• OncoZenge set a directed share issue of 1,100,000 new shares at SEK 3.00 each, raising SEK 3.3 million gross.
• Life Science Invest Fund subscribed for 1,000,000 shares; Selandia Alpha Invest took 100,000 shares.
• Proceeds earmarked for the BEAM-Pain Phase III trial, preparations for a marketing authorisation application.
• Total shares rise to 27,601,244 from 26,501,244; placement implies roughly 4% dilution.
• Pricing set at a roughly 9.5% discount to the Oct. 7 close; roughly 12.1% discount to the 5-day VWAP.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on October 07, 2026, and is solely responsible for the information contained therein.